Mass spectrometry solutions to push the limits of Drug Discovery & Development
AB SCIEX is a global leader and trusted partner in the development of advanced analytical technologies which help answer complex scientific challenges in the life sciences. Our Mass spectrometry solutions come from a strong heritage of innovative technologies which have paved the way for the development of intelligent, efficient, and advanced analytical workflows that continue to redefine LC-MS/MS.
AB SCIEX technology is central to the drug discovery and development pipeline. From the rapid structural identification and in vitro metabolic stability needs of the Early Discovery phase, through to the integrated Qual/Quant and low-level quantitation requirements of the Development phase. AB SCIEX offers an innovative set of chromatography, mass spectrometry, software and compliance & validation solutions to meet the demands of modern therapeutic drug development.
To accelerate intelligent & effective drug discovery processes, scientists worldwide have demanded greater levels of speed, efficiencies and depth of data from their LC-MS/MS solutions providers.
Fast Metabolic stability assessment for the identification of soft-spot analysis and the detection of low-level reactive metabolites have become indispensible tools in improving attrition rates, increasing the time to market and avoiding idiosyncratic adverse drug reactions down the road.
The uniquely intelligent workflows of the TripleTOFTM 5600 and QTRAP® 5500 Systems enable fast and accurate metabolic stability screening and reactive metabolite (GSH-adduct) detection. High throughput screening workflows in the discovery lab have been reinvented through the automation, information sharing and advanced monitoring features of DiscoveryQuantTM software allowing modern medicinal chemists to synthesize compounds at a rapid rate and helping early ADME/PK labs manage the increased demands for higher throughput and data quality.
Being able to find, identify and confirm both major and low-level metabolites is critical in drug discovery. Being able to accomplish this in a single analysis is a highly sought after goal.
The uniquely intelligent workflows of the AB SCIEX TripleTOFTM 5600 System and QTRAP® 5500 System allows scientist to explore novel approaches for in-vivo metabolite identification & pharmacokinetics experiments. The unmatched speed, accuracy and resolution of the TripleTOFTM5600 System in both MS and MS/MS modes can unlock previously unattainable levels of performance in simultaneous qualitative and quantitative late stage discovery.
The advantages of the unique TripleTrapTM scanning workflows of the QTRAP® 5500 System combines triple quadrupole and linear ion trap scan capabilities for true targeted and non-targeted metabolite.
The intuitative LighSightTM and MetabolitePilotTM Software platforms can automate intelligent metabolite identification allowing scientists to identify more metabolites, at lower levels, in less time with greater confidence than ever before.
With the synthesis of more unique and exotic drug candidates, the pharmaceutical industry needs to rely on technologies which can accomplish more in less time and do so in a fashion that inspires commitment to scientific integrity.
The uniquely intelligent workflows of the AB SCIEX TripleTOFTM 5600 System can unlock previously unattainable levels of performance in simultaneous qualitative and quantitative drug development workflows. The unmatched speed, accuracy and resolution of the TripleTOFTM5600 System in both MS and MS/MS modes sets the standard for definitive in-vivo metabolite identification. .
From the introduction of the API III Triple Quad which defined quantitative bioanalysis, to the barrier breaking performance levels of the QTRAP® 5500 and Triple Quad™5500 Systems, AB SCIEX has maintained its vision: providing the drug discovery & development industry with the technology they need to push the limits of discovery & development and accelerate todays discoveries into tomorrows breakthrough treatments.
With increasingly complex drug candidates comes increasingly challenging bioanalytical assays. The bold advancements in performance and versatility of the Triple Quad™ 5500 and QTRAP® 5500 Systems are clear examples of our commitment to pushing the limits of what is possible in quantitation. Our recent advancements in MRM3 Quantitation and Dried Blood Spot analysis can help you push the limits of what is possible in regulated bioanalysis.